Organovo (ONVO) Competitors $2.41 +0.04 (+1.69%) As of 03/28/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONVO vs. LSTA, LPCN, ME, CLDI, EGRX, INAB, MTEX, CLRB, SNTI, and EDSAShould you be buying Organovo stock or one of its competitors? The main competitors of Organovo include Lisata Therapeutics (LSTA), Lipocine (LPCN), 23andMe (ME), Calidi Biotherapeutics (CLDI), Eagle Pharmaceuticals (EGRX), IN8bio (INAB), Mannatech (MTEX), Cellectar Biosciences (CLRB), Senti Biosciences (SNTI), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. Organovo vs. Lisata Therapeutics Lipocine 23andMe Calidi Biotherapeutics Eagle Pharmaceuticals IN8bio Mannatech Cellectar Biosciences Senti Biosciences Edesa Biotech Lisata Therapeutics (NASDAQ:LSTA) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk. Does the MarketBeat Community favor LSTA or ONVO? Organovo received 182 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 93.33% of users gave Lisata Therapeutics an outperform vote while only 46.01% of users gave Organovo an outperform vote. CompanyUnderperformOutperformLisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67%OrganovoOutperform Votes19646.01% Underperform Votes23053.99% Do analysts prefer LSTA or ONVO? Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 538.30%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Lisata Therapeutics is more favorable than Organovo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Organovo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in LSTA or ONVO? 8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 8.2% of Organovo shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by insiders. Comparatively, 3.7% of Organovo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, LSTA or ONVO? Organovo has lower revenue, but higher earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1M20.26-$20.84M-$2.40-0.98Organovo$122K33.60-$14.67M-$10.20-0.24 Is LSTA or ONVO more profitable? Lisata Therapeutics has a net margin of 0.00% compared to Organovo's net margin of -10,151.64%. Lisata Therapeutics' return on equity of -51.19% beat Organovo's return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -51.19% -45.16% Organovo -10,151.64%-346.26%-187.53% Does the media refer more to LSTA or ONVO? In the previous week, Organovo had 7 more articles in the media than Lisata Therapeutics. MarketBeat recorded 9 mentions for Organovo and 2 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.43 beat Organovo's score of 0.46 indicating that Lisata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Lisata Therapeutics Positive Organovo Neutral Which has more volatility and risk, LSTA or ONVO? Lisata Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. SummaryLisata Therapeutics beats Organovo on 14 of the 18 factors compared between the two stocks. Remove Ads Get Organovo News Delivered to You Automatically Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONVO vs. The Competition Export to ExcelMetricOrganovoBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.10M$3.03B$5.64B$7.84BDividend YieldN/A1.55%4.59%4.01%P/E Ratio-2.8429.4223.4118.71Price / Sales33.60429.55387.6790.64Price / CashN/A168.6838.1734.64Price / Book120.503.926.894.23Net Income-$14.67M-$71.95M$3.20B$247.34M7 Day Performance-23.25%-5.63%-3.04%-2.26%1 Month Performance-69.10%-12.04%1.53%-5.78%1 Year Performance-80.50%-27.86%9.36%-0.91% Organovo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONVOOrganovo0.9961 of 5 stars$2.41+1.7%N/A-80.5%$4.10M$122,000.00-2.8420Analyst ForecastStock SplitShort Interest ↓News CoverageLSTALisata Therapeutics3.021 of 5 stars$2.33-2.1%$15.00+543.8%-24.7%$20.09M$1M-0.9330Short Interest ↓Positive NewsLPCNLipocine2.0775 of 5 stars$3.68+4.0%$10.00+171.7%-36.9%$19.69M$11.20M-4.8410ME23andMe1.2449 of 5 stars$0.73-59.2%$9.40+1,187.7%-94.3%$19.58M$208.78M-0.05770Options VolumeNews CoverageGap DownHigh Trading VolumeCLDICalidi Biotherapeutics2.2025 of 5 stars$0.73-1.9%$15.00+1,966.4%N/A$19.21M$50,000.000.0038News CoverageGap DownEGRXEagle PharmaceuticalsN/A$1.45-2.7%N/A-83.2%$18.83M$257.55M0.00100Analyst ForecastNews CoverageGap UpINABIN8bio3.0434 of 5 stars$0.23-2.1%$6.00+2,532.7%-83.4%$18.52MN/A-0.3020Short Interest ↑MTEXMannatech0.7083 of 5 stars$9.62-0.8%N/A+3.3%$18.13M$121.55M-11.88250Earnings ReportAnalyst ForecastGap DownCLRBCellectar Biosciences2.0502 of 5 stars$0.39+5.7%$17.67+4,427.6%-91.6%$17.98MN/A-0.2310Analyst ForecastShort Interest ↑SNTISenti Biosciences3.455 of 5 stars$3.72+1.1%$10.00+168.8%-9.0%$17.97M$2.56M-0.244Short Interest ↓Gap UpEDSAEdesa Biotech3.59 of 5 stars$2.56+2.4%$21.00+720.3%-39.8%$17.90MN/A-1.3720Gap Up Remove Ads Related Companies and Tools Related Companies Lisata Therapeutics Competitors Lipocine Competitors 23andMe Competitors Calidi Biotherapeutics Competitors Eagle Pharmaceuticals Competitors IN8bio Competitors Mannatech Competitors Cellectar Biosciences Competitors Senti Biosciences Competitors Edesa Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONVO) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONVO Stock Free ONVO Stock Alerts